Searchable abstracts of presentations at key conferences in endocrinology

ea0020p193 | Endocrine tumours and neoplasia | ECE2009

Effectiveness and safety of combined therapy with low dose ketoconazole and cabergoline in patients with Cushing’s disease partially responsive to monotherapy with cabergoline

Pivonello Rosario , De Leo Monica , De Martino MariaCristina , Cozzolino Alessia , Auriemma Renata S , Galdiero Mariano , Lombardi Gaetano , Colao Annamaria

The first-line treatment of Cushing’s disease is surgery, although it is effective in inducing a long-term remission in around 50% of patients with Cushing’s disease (CD). Nowadays, no pituitary tumor-directed medical treatment is available with the exception of cabergoline, which has been recently demonstrated to control cortisol secretion without major side effects in around 40% of patients with Cushing’s disease. Cabergoline has been recently demonstrated to ...

ea0014oc8.2 | Neuroendocrinology clinical | ECE2007

Effect of GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in acromegalic patients resistant to somatostatin analogues

De Martino Maria Cristina , Auriemma Renata S , Brevetti Gregorio , Galdiero Mariano , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Acromegaly is known to be associated to an increased cardiovascular risk, due to the increased prevalence of glucose intolerance and dyslipidemia and pre-atherosclerotic lesions. The aim of this study was to evaluate the effect of treatment with the GH receptor antagonist pegvisomant on cardiovascular risk and atherosclerosis in patients with acromegaly resistant to somatostatin analogues. Twelve patients (4 m, 8 f, 28–58 yrs) and 24 sex-, age- and BMI-matched controls en...

ea0014p548 | (1) | ECE2007

Effects of combined treatment with cabergoline and somatostatin analogues (SAA) on GH and IGF-I levels and tumor volume in patients with acromegaly not fully responsive to SAA

Auriemma Renata S , Galdiero Mariano , De Martino Maria Cristina , De Leo Monica , Lombardi Gaetano , Colao Annamaria , Pivonello Rosario

Dopamine agonists have been used as first or adjunctive therapy for acromegaly for many years, but relatively few studies have assessed the efficacy of a newer agonist, cabergoline (CAB) alone or in combination with somatostatin analogues (SSA). The aim of this study was to evaluate the efficacy of combined treatment with SSA plus CAB in patients with acromegaly and resistance to SSA, defined as lack of normalization of IGF-I levels after long-term (>1 year) and hig...

ea0056gp6 | Acromegaly | ECE2018

IGF-I response to pasireotide LAR treatment in acromegaly is mainly driven by somatostatin receptor subtype 2 expression

Muhammad Ammar , Coopmans Eva , Gatto Federico , Franck Sanne , Janssen Joseph , van der Lelij Aart Jan , Hofland Leo , Neggers Sebastian

Background: The response to first-generation long-acting somatostatin analogues (LA-SSA) treatment in acromegaly depends on the expression of the somatostatin receptor (SSTR) subtypes. In contrast to octreotide and lanreotide which preferentially bind to SSTR2, pasireotide targets multiple SSTRs, with the highest binding affinity for SSTR5. It has previously been suggested that SSTR5 expression could predict the response to pasireotide LAR (PAS-LAR) treatment in acromegaly.</p...

ea0056p129 | Endocrine tumours and neoplasia | ECE2018

The effect of temozolomide on pancreatic neuroendocrine tumours and role of MGMT and MMR system in temozolomide resistance

Blazevic Anela , Dogan-Oruc Fadime , Dedeci Mehtap , van Koetsveld Peter M. , Feelders Richard A. , de Herder Wouter W. , Hofland Leo J.

Background: Temozolomide (TMZ) has been suggested as a treatment option for patients with pancreatic neuroendocrine tumours (PNETs). The tumour response to TMZ has been linked to expression levels of O6-methylguanine-DNA methyltransferase (MGMT) and components of the mismatch repair (MMR) system. However, there is no in vitro data on TMZ sensitivity and the expression of MGMT and MMR components in PNETs. Moreover, the effect of TMZ exposure on chemosensitivity and exp...

ea0073pep4.3 | Presented ePosters 4: Reproductive and Developmental Endocrinology | ECE2021

Effects of a very low-calorie ketogenic diet on androgen levels in overweight/obese men: a single-arm uncontrolled study

Cignarelli Angelo , Conte Eleonora , Genchi Valentina Annamaria , Giordano Fiorella , Leo Simona Di , Perrini Sebastio , Natalicchio Annalisa , Laviola Luigi , Giorgino Francesco

Low levels of testosterone and SHBG levels are often present in subjects with overweight and obesity; functional hypogonadism further alters the metabolic balance and may drag subjects in a sort of vicious cycle, reducing exercise and energy expenditure. The very low-calorie ketogenic diet (VLCKD) has been reported to rapidly reduce body weight, glycaemia and insulinemia, but its effects on total testosterone (TT) and SHBG levels are less clear. We thus aimed to evaluate the r...

ea0075d07 | Diabetes | EYES2021

Red blood cell membrane fluidity in type 2 diabetes mellitus

Emanuele Rizzo Gaetano , Laura Leo Maria , Salvatore Raia , Linda Tartaglione , Marco De Spirito , Giuseppe Maulucci , Alfredo Pontecorvi , Dario Pitocco

Background: Cell membrane fluidity of erythrocytes in patients with type 2 diabetes can be influenced by glycosylation processes, changes in lipid homeostasis and oxidative stress.Objectives: We have measured red blood cell membrane fluidity looking for differences between healthy people and diabetic subjects and also between diabetic patients affected by macroangiopathy (vascular diabetic foot) and not.Methods: We have enrolled 32...

ea0075p05 | Pituitary and neuroendocrinology | EYES2021

A rare case of gonadotroph adenoma in a young woman

Veleno Miriam , Maggio Ettore , Morgante Cesare , Novizio Roberto , Laura Leo Maria , Policola Caterina , Locantore Pietro , Pontecorvi Alfredo

Background: Functioning gonadotroph adenomas (GA) account for 20 to 25% of all pituitary adenomas. Clinical presentation consists in multiple ovarian follicles and cysts, higher estradiol level and endometrial hyperplasia. The treatment of choice is transphenoidal tumor resection.Case Presentation: A 40 year old woman presented with abdominal pain and menstrual cycle dysfunctions. Hormonal evaluation showed: FSH:13.8 mU/ml, estradiol:1549 pg/ml, PRL:81.7...

ea0092ps2-16-07 | Thyroid Cancer clinical 2 | ETA2023

Tumor lysis syndrome during neoadjuvant selpercatinib treatment for medullary thyroid cancer

Trevisan Matteo , De Leo Simone , Vanessa Re Sarto Giulia , Moneta Claudia , Pirovano Marta , Colombo Carla , Cosmai Laura , Fugazzola Laura

Selpercatinib is a specific RET inhibitor, highly effective in the treatment of advanced RET-mutant medullary thyroid carcinoma (MTC). The consequences of selpercatinib administration in MTC patients who have not undergone thyroid surgery are still unknown. We report the case of an 84-year-old man undergoing investigations for worsening diarrhea and weight loss. Upon a neck ultrasound scan and blood exams that pointed out high levels of both calcitonin (CT, 20.583 ng/l) and ca...

ea0095p147 | Pituitary and Growth 2 | BSPED2023

Testing a screening algorithm for the identification of growth-disorders for use in UK children

Orr Joanna , Thaventhiran Thilipan , Freer Joseph , Walton Robert , Morris Joan K , Dunkel Leo , Prendergast Andrew J. , Storr Helen L.

Background: Screening algorithms for the identification of growth-disorders are routinely used in several countries. In the UK, the use of the Coventry consensus for the referral of children with suspected growth-disorders performs poorly compared to more sophisticated screening mechanisms used elsewhere. We aimed to test an algorithm developed to screen for growth-disorders in 2- to 8-year-old UK children.Methods: The a...